Author

Zheng-Jia Liu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Clinical characteristics of immune-related adverse events after immune checkpoint inhibitor therapy with or without chemotherapy in patients with antinuclear antibody-positive malignancies

Background Antinuclear antibodies (ANA) are detected in cancer patients before ICI therapy, but their association with immune-related adverse events (irAEs) and outcomes is uncertain. This study aimed to characterize irAEs and tolerability in ANA-positive patients receiving ICI ± chemotherapy, and explore implications...

Hang-Hui Yu, En-Yong Dai, Jian-Peng Xing et al. · Frontiers in Immunology · 0 citations

Review Open access Sep 2026

Immunotherapy in advanced biliary tract cancer: current status and future directions

Biliary tract cancers (BTCs) are aggressive, molecularly heterogeneous malignancies, and most patients present with unresectable or metastatic disease at diagnosis. For more than a decade, gemcitabine–platinum chemotherapy served as the first-line standard of care, with only modest survival benefit. The phase 3 TOPAZ-1...

Wu Lv, Zheng-Jia Liu, Hui-Shuang Du et al. · Frontiers in Pharmacology · 0 citations